SG11202113375PA - Treatments of angioedema - Google Patents

Treatments of angioedema

Info

Publication number
SG11202113375PA
SG11202113375PA SG11202113375PA SG11202113375PA SG11202113375PA SG 11202113375P A SG11202113375P A SG 11202113375PA SG 11202113375P A SG11202113375P A SG 11202113375PA SG 11202113375P A SG11202113375P A SG 11202113375PA SG 11202113375P A SG11202113375P A SG 11202113375PA
Authority
SG
Singapore
Prior art keywords
angioedema
treatments
Prior art date
Application number
SG11202113375PA
Inventor
Edward Paul Feener
Sally Louise Marsh
Andreas Maetzel
Michael David Smith
Christopher Martyn Yea
Original Assignee
Kalvista Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalvista Pharmaceuticals Ltd filed Critical Kalvista Pharmaceuticals Ltd
Publication of SG11202113375PA publication Critical patent/SG11202113375PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
SG11202113375PA 2019-06-14 2020-06-15 Treatments of angioedema SG11202113375PA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861758P 2019-06-14 2019-06-14
GBGB1910125.2A GB201910125D0 (en) 2019-07-15 2019-07-15 Treatments of angioedema
PCT/GB2020/051441 WO2020249979A1 (en) 2019-06-14 2020-06-15 Treatments of angioedema

Publications (1)

Publication Number Publication Date
SG11202113375PA true SG11202113375PA (en) 2021-12-30

Family

ID=67700187

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202113375PA SG11202113375PA (en) 2019-06-14 2020-06-15 Treatments of angioedema

Country Status (17)

Country Link
US (1) US20220226293A1 (en)
EP (1) EP3982961A1 (en)
JP (1) JP2022537913A (en)
KR (1) KR20220024221A (en)
CN (2) CN113993520A (en)
AR (1) AR119159A1 (en)
AU (1) AU2020293616A1 (en)
BR (1) BR112021024447A2 (en)
CA (1) CA3142220A1 (en)
CL (2) CL2021003243A1 (en)
GB (1) GB201910125D0 (en)
IL (1) IL288612A (en)
MA (1) MA56188A (en)
MX (1) MX2021014558A (en)
SG (1) SG11202113375PA (en)
TW (1) TW202112371A (en)
WO (1) WO2020249979A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
EP4010333A1 (en) 2019-08-09 2022-06-15 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
EP4288036A1 (en) 2022-04-27 2023-12-13 Kalvista Pharmaceuticals Limited Formulations of a plasma kallikrein inhibitor
CN116003386B (en) * 2022-11-20 2024-03-26 药康众拓(北京)医药科技有限公司 Deuterated N-benzyl pyridone pyrazole carboxamides, pharmaceutical composition and application

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
GB9019558D0 (en) 1990-09-07 1990-10-24 Szelke Michael Enzyme inhibitors
SE9301911D0 (en) 1993-06-03 1993-06-03 Ab Astra NEW PEPTIDE DERIVATIVES
US5589467A (en) 1993-09-17 1996-12-31 Novo Nordisk A/S 2,5',N6-trisubstituted adenosine derivatives
GB0205527D0 (en) 2002-03-08 2002-04-24 Ferring Bv Inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AU2007281220B2 (en) 2006-07-31 2013-08-15 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
DE102006050672A1 (en) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh New glycylglycine derivatives with a benzylsulfonylamido group and an amidino-organylamido group at the opposite chain ends, used in drugs for reducing loss of blood, e.g. in operations
JP2013121919A (en) 2010-03-25 2013-06-20 Astellas Pharma Inc Plasma kallikrein inhibitor
ES2483802T3 (en) 2010-07-07 2014-08-07 The Medicines Company (Leipzig) Gmbh Serine protease inhibitors
EP2595986A2 (en) 2010-07-14 2013-05-29 Addex Pharma SA Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
GB2494851A (en) 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
GB201300304D0 (en) 2013-01-08 2013-02-20 Kalvista Pharmaceuticals Ltd Benzylamine derivatives
EP3305778B1 (en) 2013-05-23 2022-01-19 Kalvista Pharmaceuticals Limited Inhibitors of plasma kallikrein
GB201421083D0 (en) * 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201721515D0 (en) * 2017-12-21 2018-02-07 Kalvista Pharmaceuticals Ltd Dosage forms comprising a plasma kallikrein inhibtor

Also Published As

Publication number Publication date
IL288612A (en) 2022-02-01
MA56188A (en) 2022-04-20
US20220226293A1 (en) 2022-07-21
CN113993520A (en) 2022-01-28
GB201910125D0 (en) 2019-08-28
CA3142220A1 (en) 2020-12-17
MX2021014558A (en) 2022-04-06
TW202112371A (en) 2021-04-01
BR112021024447A2 (en) 2022-01-18
CL2023000699A1 (en) 2023-10-30
CN118078821A (en) 2024-05-28
JP2022537913A (en) 2022-08-31
EP3982961A1 (en) 2022-04-20
KR20220024221A (en) 2022-03-03
AR119159A1 (en) 2021-12-01
WO2020249979A1 (en) 2020-12-17
AU2020293616A1 (en) 2022-01-27
CL2021003243A1 (en) 2022-09-30

Similar Documents

Publication Publication Date Title
IL288612A (en) Treatments of angioedema
IL288615A (en) Treatments of hereditary angioedema
GB201804514D0 (en) Treatment of pyroptosis
IL291362A (en) Treatment of syngap1 encephalopathy
GB201804515D0 (en) Treatment of necroptosis
IL290756A (en) Treatment of azoles
EP3758702A4 (en) Treatment of hereditary angioedema
GB201907305D0 (en) Treatment of conditions
GB201914296D0 (en) Treatment
IL290983A (en) Methods of treatment
GB201918853D0 (en) Methods of treatment
IL288526A (en) Thiarabine- and thiarabine prodrug-based treatments
GB201900942D0 (en) Methods of treatment
GB201917908D0 (en) Novel treatments
GB201913636D0 (en) Novel treatments
GB201904714D0 (en) Novel treatments
GB201917253D0 (en) Treatment of conditions
IL287250A (en) Method of treatment
IL276421A (en) Methods of testosterone therapy
PL3955933T3 (en) Treatment of migraine
EP3979789A4 (en) Treatment of saprolegniasis
GB201906975D0 (en) Treatment of ards
GB201912760D0 (en) Treatment
AU2019903451A0 (en) Methods of treatment
GB201912335D0 (en) Treatment